We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -27.50 | -1.55% | 1,747.50 | 1,747.50 | 1,748.50 | 1,770.00 | 1,746.00 | 1,770.00 | 912,483 | 09:24:47 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.61 | 72.01B |
From May 2019 to May 2024
By Ian Walker
GlaxoSmithKline PLC said late Wednesday that it has stopped enrolling patients in a trial studying a combination drug therapy using feladilimab in cancer patients.
The pharmaceutical giant said it has decided to stop enrolling patients in the Phase 2 Induce-3 trial following a recommendation by the independent data monitoring committee. It has also decided to stop the Induce-4 Phase 2 trial.
The Induce-3 trial was investigating feladilimab in combination with pembrolizumab compared with a placebo in combination with pembrolizumab in patients with PD-L1 positive recurrent locally advanced or metastatic head and neck squamous cell carcinoma.
The Induce-4 trial was studying feladilimab compared with a placebo in combination with pembrolizumab and chemotherapy.
Glaxo said the data taken so far will be used to assess the impact on the overall clinical development program for feladilimab.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
April 15, 2021 01:44 ET (05:44 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
